GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Market Cap

Avadel Pharmaceuticals (STU:AWK) Market Cap : €1,403.35 Mil (As of May. 17, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Avadel Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was €15.1. Avadel Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 96.10 Mil. Therefore, Avadel Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was €1,451.06 Mil.

Avadel Pharmaceuticals's quarterly market cap increased from Sep. 2023 (€871.63 Mil) to Dec. 2023 (€1,167.73 Mil) and increased from Dec. 2023 (€1,167.73 Mil) to Mar. 2024 (€1,451.06 Mil).

Avadel Pharmaceuticals's annual market cap declined from Dec. 2021 (€404.48 Mil) to Dec. 2022 (€392.99 Mil) but then increased from Dec. 2022 (€392.99 Mil) to Dec. 2023 (€1,167.73 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Avadel Pharmaceuticals's Enterprise Value for Today is €1,323.80 Mil.


Avadel Pharmaceuticals Market Cap Historical Data

The historical data trend for Avadel Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Market Cap Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 234.50 291.98 404.48 392.99 1,167.73

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 541.62 1,241.56 871.63 1,167.73 1,451.06

Competitive Comparison of Avadel Pharmaceuticals's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Market Cap falls into.



Avadel Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Avadel Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€13*89.825
=€1,167.73

Avadel Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=€15.1*96.0969
=€1,451.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avadel Pharmaceuticals  (STU:AWK) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Avadel Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (STU:AWK) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.